Pentapeptide enkephalin analogue that acts on opioid receptors in nerve terminals to reduce acetylcholine release at neuromuscular junctions. Studied in combination with argireline for synergistic expression-line reduction.
Leuphasyl is a synthetic pentapeptide used in cosmetic skincare formulations for reducing the appearance of expression lines. What makes it distinct from Acetyl Hexapeptide-3 (Argireline) and SNAP-8 is that it works through a different mechanism entirely. Rather than mimicking SNAP-25 and interfering with the docking proteins that release neurotransmitters, Leuphasyl mimics an enkephalin — a naturally occurring peptide in the nervous system that acts on opioid receptors in nerve terminals to calm their activity. The effect is a reduction in how readily the nerve fires and releases acetylcholine, which means fewer and slightly weaker muscle contractions. Because it targets a different step in the signaling chain than Argireline-style peptides, it is considered a complementary approach rather than a substitute for them.
The Enkephalin Pathway — How It Differs
Enkephalins are naturally occurring neuropeptides that bind to opioid receptors on nerve terminals and reduce their excitability — essentially acting as a natural brake on nerve firing. Leuphasyl was designed to mimic this action at the neuromuscular junction in facial muscles. By reducing nerve terminal activity before the signal even reaches the SNARE protein docking step, it targets an earlier point in the contraction chain than Argireline or SNAP-8 do. This makes it a different tool rather than a duplicate one.
Expression Line Reduction Research
Small cosmetic studies have examined Leuphasyl in topical formulations for expression line reduction. Reported results show modest improvements in wrinkle depth with regular use over several weeks — consistent with the gradual, subtle mechanism. Most research is industry-sponsored and involves combination products. The effects are cosmetic and surface-level.
Combination Use with Argireline-Style Peptides
Because Leuphasyl targets the nerve terminal's excitability while Argireline and SNAP-8 target the neurotransmitter release machinery itself, they address sequential steps in the same signaling pathway. Cosmetic researchers have studied them in combination on the hypothesis that targeting both steps simultaneously produces a greater reduction in muscle contraction intensity than either peptide alone. Some formulation studies report additive effects with this approach.
Acts through the enkephalin/opioid receptor pathway — a different mechanism than SNAP-25-mimicking peptides.
Small cosmetic studies show modest expression line reductions with regular topical use.
Combination with Argireline-style peptides is studied for potential additive effects through sequential pathway targeting.
No systemic activity at concentrations used in cosmetic products.
Leuphasyl research consists entirely of small, industry-funded cosmetic studies. Effects are modest and cosmetic — they represent subtle changes in expression line appearance, not structural alterations to underlying tissue. Large independent randomized controlled trials do not exist. It is a cosmetic ingredient regulated as such, not a drug, and should not be compared to prescription or injectable interventions. The enkephalin mechanism is pharmacologically plausible but its magnitude of effect in topical application is modest.
Every time a facial muscle contracts, a nerve signal travels from the brain down to the muscle, where it triggers the release of acetylcholine — the chemical that tells the muscle fiber to shorten. That signal can be reduced at two points: before the acetylcholine is released, or at the moment of release itself. Argireline and SNAP-8 work at the moment of release, competing with proteins involved in the release machinery. Leuphasyl works one step earlier, at the nerve terminal itself. It mimics enkephalin peptides that naturally bind to opioid receptors on nerve terminals and reduce how excitable the nerve is — meaning the signal that reaches the release machinery in the first place is slightly weaker. The downstream result is the same: a modest reduction in how forcefully the muscle contracts, and over time with regular use, a potential reduction in expression line depth. The effects are gradual, subtle, and reversible.
Leuphasyl is well-tolerated as a cosmetic ingredient at concentrations used in skincare products. There is no systemic absorption of concern at topical use levels. Skin irritation is uncommon. It is a cosmetic ingredient subject to cosmetic regulatory standards — not a drug and not evaluated by the FDA for effectiveness as a therapeutic agent.
Preliminary
Most evidence comes from preclinical studies and case reports. Human data is limited and more research is needed.
Published Research Ranges
Topical 5% in research formulations; often combined with argireline
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Leuphasyl Inhibits Neuronal Excitation via Enkephalin Receptor Modulation
International Journal of Cosmetic Science • 2009
• DOI: 10.1111/j.1468-2494.2009.00481.x
The immediate effects of cervical spine manipulation on pain and biochemical markers in females with acute non-specific mechanical neck pain: a randomized clinical trial
Bioactive peptides from food science to pharmaceutical industries: Their mechanism of action, potential role in cancer treatment and available resources
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.